Video

Dr. Pelosof on the Increasing Incidence of Never Smokers in NSCLC

Lorraine Pelosof, MD, PhD, from The University of Texas Southwestern Medical Center, discusses a study looking at the incidence of never smokers diagnosed with non-small cell lung cancer (NSCLC).

Lorraine Pelosof, MD, PhD, assistant professor, Division of Hematology/Oncology, The University of Texas Southwestern Medical Center, discusses a study looking at the incidence of never smokers diagnosed with non-small cell lung cancer (NSCLC).

It’s known that 10-15% of patients with NSCLC are never smokers. Whether or not this proportion is increasing, Pelosof says, has been up for debate. This study analyzed about 10,000 patients with NSCLC and 1,500 patients with small cell lung cancer (SCLC) and found that the proportion of never smokers in NSCLC is increasing, but has remained constant in SCLC.

Pelosof says it’s understood that the biology of non-smokers and smokers is different. This study speaks to what further work needs to be done and how care should be directed.

<<<

View more from the 2015 World Conference on Lung Cancer

Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss testing for ALK-positive and ROS1-positive non–small cell lung cancer.
Nicolas Girard, MD
Sally Lau, MD